Genomic Changes as Prognostic Markers in Breast Cancer
Author Information
Author(s): Han Wonshik, Han Mi-Ryung, Kang Jason Jongho, Bae Ji-Yeon, Lee Ji Hyun, Bae Young Ju, Lee Jeong Eon, Shin Hyuk-Jae, Hwang Ki-Tae, Hwang Sung-Eun, Kim Sung-Won, Noh Dong-Young
Primary Institution: Seoul National University College of Medicine
Hypothesis
Can genomic alterations predict prognosis and tamoxifen responsiveness in ER-positive breast cancer?
Conclusion
Genomic alterations detected by array CGH can differentiate between recurrence and non-recurrence groups in ER-positive breast cancer patients.
Supporting Evidence
- Loss of 11p15 and 1p36 and gain of 8q21 are significantly associated with distant recurrence of the disease within 5 years of diagnosis.
- Patients in the Recurrence group showed a significantly different pattern of chromosomal gain and loss than patients in the Non-recurrence group.
Takeaway
This study looked at breast cancer samples to see if changes in their DNA could help predict if patients would get worse after treatment. They found some changes that could be important for doctors to know.
Methodology
Array comparative genomic hybridization was performed on 28 fresh-frozen ER-positive breast cancer tissues to assess copy number changes.
Limitations
The study had a small sample size and relied on fresh-frozen tissues, which limited availability.
Participant Demographics
All participants were women diagnosed with ER-positive invasive ductal carcinoma who received tamoxifen treatment.
Statistical Information
P-Value
<0.001
Confidence Interval
95% confidence interval: 2.7–55.4
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website